272 related articles for article (PubMed ID: 8683243)
41. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
[TBL] [Abstract][Full Text] [Related]
42. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.
Schiller JH
Semin Oncol; 1996 Aug; 23(4 Suppl 8):78-82. PubMed ID: 8783672
[TBL] [Abstract][Full Text] [Related]
43. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
De Vos FY; Bos AM; Schaapveld M; de Swart CA; de Graaf H; van der Zee AG; Boezen HM; de Vries EG; Willemse PH
Gynecol Oncol; 2005 Apr; 97(1):60-7. PubMed ID: 15790438
[TBL] [Abstract][Full Text] [Related]
44. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
[TBL] [Abstract][Full Text] [Related]
45. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Hartmann JT; Knop S; Fels LM; van Vangerow A; Stolte H; Kanz L; Bokemeyer C
Anticancer Drugs; 2000 Jan; 11(1):1-6. PubMed ID: 10757556
[TBL] [Abstract][Full Text] [Related]
46. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
[TBL] [Abstract][Full Text] [Related]
47. [A pilot trial of high dose CEP (cyclophosphamide, epirubicin, cis-platinum) therapy in patients with advanced and recurrent ovarian cancer].
Hiura M; Ogawa M; Nozawa S; Kudo R; Kuwabara Y; Takahashi T; Takayama M; Tateno M; Ohashi Y; Yakushiji M
Gan To Kagaku Ryoho; 2000 Apr; 27(4):585-91. PubMed ID: 10791001
[TBL] [Abstract][Full Text] [Related]
48. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
49. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Giles FJ; Shi GG; Cortes JE; Thomas D; Keating AR; Kantarjian HM; Keating MJ; O'Brien SM
Cancer Chemother Pharmacol; 2003 Sep; 52(3):223-8. PubMed ID: 12783199
[TBL] [Abstract][Full Text] [Related]
50. Infusional cisplatin plus cyclophosphamide in advanced ovarian cancer.
Lokich J; Zipoli T; Green R
Cancer; 1986 Dec; 58(11):2389-92. PubMed ID: 3768834
[TBL] [Abstract][Full Text] [Related]
51. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
[TBL] [Abstract][Full Text] [Related]
52. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
53. Use of amifostine in the therapy of osteosarcoma in children and adolescents.
Petrilli AS; Oliveira DT; Ginani VC; Kechichian R; Dishtchekenian A; Filho Wde M; Tanaka C; Dias CG; Latorre Mdo R; Brunetto AL; Cardoso H; Almeida MT; de Camargo B
J Pediatr Hematol Oncol; 2002; 24(3):188-91. PubMed ID: 11990304
[TBL] [Abstract][Full Text] [Related]
54. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762
[TBL] [Abstract][Full Text] [Related]
55. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Hartmann JT; Fels LM; Knop S; Stolt H; Kanz L; Bokemeyer C
Invest New Drugs; 2000 Aug; 18(3):281-9. PubMed ID: 10958599
[TBL] [Abstract][Full Text] [Related]
56. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
[TBL] [Abstract][Full Text] [Related]
57. Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma.
Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Renody N; Mularoni E; Soubrane C; Weil M; Mortier N; Khayat D
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-38-S2-40. PubMed ID: 9045335
[TBL] [Abstract][Full Text] [Related]
58. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
59. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities.
Gandara DR; Nahhas WA; Adelson MD; Lichtman SM; Podczaski ES; Yanovich S; Homesley HD; Braly P; Ritch PS; Weisberg SR
J Clin Oncol; 1995 Feb; 13(2):490-6. PubMed ID: 7844610
[TBL] [Abstract][Full Text] [Related]
60. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
McGuire WP; Hoskins WJ; Brady MF; Homesley HD; Creasman WT; Berman ML; Ball H; Berek JS; Woodward J
J Clin Oncol; 1995 Jul; 13(7):1589-99. PubMed ID: 7602348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
